Takeshima, Takao
Sakai, Fumihiko
Wang, Xinyu http://orcid.org/0009-0009-3151-8092
Yamato, Kentaro http://orcid.org/0000-0002-5027-6289
Kojima, Yoshitsugu http://orcid.org/0000-0002-0286-8765
Zhang, Yilong http://orcid.org/0009-0009-3139-3824
Bennison, Craig http://orcid.org/0000-0001-8658-5510
Simons, Martijn J. H. G. http://orcid.org/0000-0001-5248-1676
Article History
Accepted: 7 April 2024
First Online: 21 May 2024
Declarations
:
: This work was supported by Otsuka Pharmaceuticals Co., Ltd. The funding source had a supervising role in conducting the study and in preparing the manuscript. The open access fee was paid by Otsuka Pharmaceuticals Co., Ltd.
: Takao Takeshima reports consulting fees or honorarium by Otsuka, Amgen, Eli-Lilly, Daiichi Sankyo, Shionogi, Bioheaven, and Lundbeck and being an advisor of Hedgehog MedTech and Sawai. Fumihiko Sakai reports consulting fees or honorarium by Otsuka, Amgen, Eli-Lilly, and Daiichi Sankyo. Xinyu Wang was employed by Otsuka Pharmaceutical Co., Ltd. during the conduct of the study and reports no conflicts of interest. Kentaro Yamato, Yoshitsugu Kojima, and Yilong Zhang are employed by Otsuka Pharmaceutical Co., Ltd. and report no conflicts of interest. Otsuka Pharmaceutical Co., Ltd. launched fremanezumab in Japan. Craig Bennison and Martijn Simons are employed by OPEN Health and report consulting fees from Otsuka. OPEN Health is a consultancy firm that was contracted by Otsuka to conduct the study and write the manuscript.
: The model developed during the current study is not publicly available due to confidentiality. The input data supporting the model are from previously reported publications and reports, which have been cited. No new data were generated or analyzed during the current study.
: Not applicable.
: Not applicable.
: Not applicable.
: Data analyses were performed in R statistical software and the model was created and analyzed in Excel.
: Conceptualization and design: XW, KY, YK, YZ, CB, MS. Data acquisition: XW, YZ. Methodology: TT, FS, XW, KY, YK, YZ, CB, MS. Formal analysis and interpretation of the data: XW, KY, YK, YZ, CB, MS. Validation: TT, FS, XW, KY, YK, YZ, CB, MS. Writing original draft: XW, YZ, CB, MS. Writing review and editing: TT, FS, XW, KY, YK, YZ, CB, MS. Critical revision of the article for important intellectual content: TT, FS, XW, KY, YK, YZ, CB, MS.